Shaakir Hasan, DO
Radiation Oncology · Mansfield, OHNPI 1316367931
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,800 of the $2,746 with a category attached, or 65.5%. Davol Inc. accounts for 65.5% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2021 at $1,816 and has fallen 98.4% since, to $29 in 2025.
Across 12 payments — averaging $228.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Davol Inc.$2K
- AstraZeneca$630
- Boston Scientific$123
- Sumitomo Pharma America, Inc.$74
- Teleflex LLC$35
- Merck$29
- plus $56 from 3 others
What the payments were for
- Consulting fees$55020%
- Speaking & faculty fees$1,80066%
- Food & beverage$39614%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Davol Inc. | 1 | $1,800 |
| AstraZeneca | 2 | $630 |
| Boston Scientific | 1 | $123 |
| Sumitomo Pharma America, Inc. | 3 | $74 |
| Teleflex LLC | 1 | $35 |
| Merck | 1 | $29 |
| Genentech USA, Inc. | 1 | $25 |
| Myovant Sciences Inc. | 1 | $16 |
| Palette Life Sciences, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TAGRISSO$525
- GENERAL - THERAPIES$123
- IMFINZI$105
How this compares
$2,746 in reported general payments places this provider in the 80th percentile of 255 radiation oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 36 | $487 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Mansfield
- Steven KurtzmanGarfield Heights$833K
- Joshua PalmerColumbus$123K
- Norleena PoynterSandusky$90K
- Daniel SprattCleveland$86K
- Shlomo KoyfmanCleveland$72K
- Gerald SokolCleveland$61K
- Peter FriedFairfield$45K
- Rahul TendulkarCleveland$26K
- Sujith BaligaColumbus$26K
- Anthony ParavatiKettering$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.